miR-34b/c rs4938723 T>C Decreases Neuroblastoma Risk: A Replication Study in the Hunan Children

Table 2

Association between miR34b/c rs4938723 T>C polymorphism and clinical parameters.

Variables	Cases/controls		OR (95% CI)		AOR (95% CI)^a	^a
	TT	TC/CC
	No. (%)	No. (%)
Age (month)
≤18	42/36 (25.9)/(13.3)	27/66 (16.7)/(24.4)	0.35 (0.19-0.66)	0.001	0.35 (0.18-0.67)	0.002
>18	58/81 (35.8)/(30.0)	35/87 (21.6)/(32.2)	0.56 (0.34-0.94)	0.029	0.55 (0.32-0.94)	0.027
Gender
Females	49/52 (30.2)/(19.2)	30/77 (18.5)/(28.5)	0.41 (0.23-0.74)	0.003	0.45 (0.24-0.82)	0.010
Males	51/65 (31.5)/(24.1)	32/76 (19.7)/(28.1)	0.54 (0.31-0.93)	0.027	0.52 (0.29-0.90)	0.020
Sites of origin
Adrenal gland	17/117 (10.5)/(43.3)	14/153 (8.64)/(56.7)	0.63 (0.30-1.33)	0.225	0.65 (0.31-1.38)	0.265
Retroperitoneal	55/117 (33.9)/(43.3)	23/153 (14.2)/(56.7)	0.32 (0.19-0.55)	<0.0001	0.35 (0.20-0.60)	0.0002
Mediastinum	16/117 (9.87)/(43.3)	20/153 (12.3)/(56.7)	0.96 (0.48-1.93)	0.900	0.96 (0.48-1.95)	0.917
Others	12/117 (7.41)/(43.3)	5/153 (3.08)/(56.7)	0.32 (0.11-0.93)	0.036	0.32 (0.11-0.94)	0.039
Clinical stages
I	23/117 (14.2)/(43.3)	25/153 (15.4)/(56.7)	0.83 (0.45-1.54)	0.556	0.86 (0.46-1.61)	0.645
II	15/117 (9.26)/(43.3)	7/153 (4.32)/(56.7)	0.36 (0.14-0.90)	0.030	0.35 (0.14-0.89)	0.027
III	34/117 (21.0)/(43.3)	20/153 (12.3)/(56.7)	0.45 (0.25-0.82)	0.009	0.45 (0.25-0.83)	0.010
IV	28/117 (17.3)/(43.3)	9/153 (5.55)/(56.7)	0.25 (0.11-0.54)	0.0005	0.26 (0.12-0.60)	0.001
4s	0/117 (0.00)/(43.3)	1/153 (0.006)/(56.7)	—	—	—	—
I+II+4s	38/117 (23.4)/(43.3)	32/153 (19.7)/(56.7)	0.64 (0.38-1.09)	0.103	0.65 (0.38-1.10)	0.110
III+IV	62/117 (38.3)/(43.3)	29/153 (17.9)/(56.7)	0.36 (0.22-0.59)	<0.0001	0.38 (0.23-0.63)	0.0002

OR: odds ratio; CI: confidence interval; AOR: adjusted odds ratio.^aAdjusted for age and gender, omitting the corresponding stratify factor.